Efficacy and Safety of Aflibercept 8 mg in PHOTON Trial in DMO

Opinion
Video

Dr. Marion Munk examines the Phase 2/3 clinical trial of high-dose aflibercept (8 mg) in diabetic macular oedema, presenting key outcomes and clinical implications of the data.

Recent Videos
3 experts are featured in this series.
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
A crystal ball sits on a small platform, surrounded by misty fog. ©alexkich – stock.adobe.com

Retinal biomarkers in OCT imaging may have predictive applications for nAMD

Lynda Charters
February 17th 2025
Article

The authors evaluated shallow irregular pigment epithelial detachment, subretinal hyperreflective material, subretinal fluid, intraretinal fluid and other baseline OCT biomarkers

A map of Italy with a magnifying glass resting atop it. Image credit: ©sharafmaksumov – stock.adobe.com

Italian study illuminates positive outcomes and common complications of SING IMT implantation

Lynda Charters
February 6th 2025
Article

The implant was tested in eyes of patients with bilateral age-related macular degeneration who underwent cataract surgery

A gloved hand holding a syringe, superimposed over the European Union flag. Image credit: ©Savvapanf Photo – stock.adobe.com

European Medicines Agency CHMP adopts positive opinions for two aflibercept biosimilars

Hattie Hayes
February 3rd 2025
Article

Pavblu and Skojoy, both from Amgen, are indicated for the treatment of neovascular age-related macular degeneration

An elderly woman undergoes an eye exam. Image credit: ©kasto – stock.adobe.com

SeaBeLife announces preclinical efficacy results for SBL03 topical ophthalmic gel

Hattie Hayes
January 30th 2025
Article

The gel addresses necrotic retinal cell death in dry age-related macular degeneration and geographic atrophy without requiring injections

Apellis Pharmaceuticals receives Australian approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy

Apellis Pharmaceuticals receives Australian approval of pegcetacoplan (Syfovre) for treatment of geographic atrophy

Martin David Harp
January 28th 2025
Article

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

The office of the Agence Nationale de Sécurité du Médicament in Saint-Denis, France. ©HJBC – stock.adobe.com

PulseSight Therapeutics submits Clinical Trial Authorisation for phase I trial of PST-611

Hattie Hayes
January 16th 2025
Article

The transferrin vectorised therapy is being investigated for use in patients with dry age-related macular degeneration and geographic atrophy

© 2025 MJH Life Sciences

All rights reserved.